RecruitingNot ApplicableNCT05431738

Anti-Migration System for Anti-reflux Oeso-gastric Stent (ANTIMIG)

Esophageal Stent With or Without Anti-migration Device for Tumors of the Gastroesophageal Junction: Multicenter Randomized Controlled Study. ANTIMIG Study


Sponsor

Société Française d'Endoscopie Digestive

Enrollment

180 participants

Start Date

Sep 1, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

The aim of this prospective, controlled, randomized, multicentre, single-blind study is to compare the rate of intragastric migration of 2 types of esophageal stents with and without an anti-migration device placed for locally advanced or metastatic malignant stenosis of the gastroesophageal junction.


Eligibility

Min Age: 18 YearsMax Age: 91 Years

Inclusion Criteria6

  • Patient of both sexes aged 18 or over.
  • Patient admitted to one of the investigation centers for dysphagia due to tumoral stenosis of the gastroesophageal junction, locally advanced or metastatic.
  • Patient ASA 1, ASA 2, ASA 3
  • Absence of participation in another clinical study
  • Signed Informed Consent
  • Patients benefiting from the social security system.

Exclusion Criteria8

  • Patient referred for stenosis by extrinsic compression by an extra digestive mass
  • Patients with contraindications relating to the procedures essential for the introduction of a stent
  • Mediastinal radiotherapy or esophageal surgery history
  • Patient under 18 or over 90
  • Patient ASA 4, ASA 5
  • Pregnant Woman
  • Patient unable to give personal consent
  • Absence of signed informed consent

Interventions

DEVICEGastroesophageal stent placement

A gastroesophageal stent is placed during a digestive endoscopy performed under general anesthesia, under endoscopic and fluoroscopic control


Locations(1)

French Society of Digestive Endoscopy

Paris, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05431738


Related Trials